FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2147124443> ?p ?o ?g. }

• W2147124443 endingPage "e14" @default.
• W2147124443 startingPage "e14" @default.
• W2147124443 abstract "Leber congenital amaurosis (LCA) is the most severe form of inherited retinal degeneration, with an onset in the first year of life. The most frequent mutation that causes LCA, present in at least 10% of individuals with LCA from North-American and Northern-European descent, is an intronic mutation in CEP290 that results in the inclusion of an aberrant exon in the CEP290 mRNA. Here, we describe a genetic therapy approach that is based on antisense oligonucleotides (AONs), small RNA molecules that are able to redirect normal splicing of aberrantly processed pre-mRNA. Immortalized lymphoblastoid cells of individuals with LCA homozygously carrying the intronic CEP290 mutation were transfected with several AONs that target the aberrant exon that is incorporated in the mutant CEP290 mRNA. Subsequent RNA isolation and reverse transcription-PCR analysis revealed that a number of AONs were capable of almost fully redirecting normal CEP290 splicing, in a dose-dependent manner. Other AONs however, displayed no effect on CEP290 splicing at all, indicating that the rescue of aberrant CEP290 splicing shows a high degree of sequence specificity. Together, our data show that AON-based therapy is a promising therapeutic approach for CEP290-associated LCA that warrants future research in animal models to develop a cure for this blinding disease. Leber congenital amaurosis (LCA) is the most severe form of inherited retinal degeneration, with an onset in the first year of life. The most frequent mutation that causes LCA, present in at least 10% of individuals with LCA from North-American and Northern-European descent, is an intronic mutation in CEP290 that results in the inclusion of an aberrant exon in the CEP290 mRNA. Here, we describe a genetic therapy approach that is based on antisense oligonucleotides (AONs), small RNA molecules that are able to redirect normal splicing of aberrantly processed pre-mRNA. Immortalized lymphoblastoid cells of individuals with LCA homozygously carrying the intronic CEP290 mutation were transfected with several AONs that target the aberrant exon that is incorporated in the mutant CEP290 mRNA. Subsequent RNA isolation and reverse transcription-PCR analysis revealed that a number of AONs were capable of almost fully redirecting normal CEP290 splicing, in a dose-dependent manner. Other AONs however, displayed no effect on CEP290 splicing at all, indicating that the rescue of aberrant CEP290 splicing shows a high degree of sequence specificity. Together, our data show that AON-based therapy is a promising therapeutic approach for CEP290-associated LCA that warrants future research in animal models to develop a cure for this blinding disease." @default.
• W2147124443 created "2016-06-24" @default.
• W2147124443 creator A5020648798 @default.
• W2147124443 creator A5049656883 @default.
• W2147124443 creator A5051555445 @default.
• W2147124443 creator A5056877021 @default.
• W2147124443 creator A5078101996 @default.
• W2147124443 creator A5078593465 @default.
• W2147124443 date "2012-01-01" @default.
• W2147124443 modified "2023-10-16" @default.
• W2147124443 title "Antisense Oligonucleotide (AON)-based Therapy for Leber Congenital Amaurosis Caused by a Frequent Mutation in CEP290" @default.
• W2147124443 cites W1623115833 @default.
• W2147124443 cites W1987677050 @default.
• W2147124443 cites W1988498783 @default.
• W2147124443 cites W1989195101 @default.
• W2147124443 cites W1995140705 @default.
• W2147124443 cites W1997182621 @default.
• W2147124443 cites W2002914110 @default.
• W2147124443 cites W2010757394 @default.
• W2147124443 cites W2013912153 @default.
• W2147124443 cites W2013912255 @default.
• W2147124443 cites W2022040013 @default.
• W2147124443 cites W2022628246 @default.
• W2147124443 cites W2042293587 @default.
• W2147124443 cites W2042396822 @default.
• W2147124443 cites W2045031393 @default.
• W2147124443 cites W2058077945 @default.
• W2147124443 cites W2061607192 @default.
• W2147124443 cites W2066041050 @default.
• W2147124443 cites W2076018659 @default.
• W2147124443 cites W2090849645 @default.
• W2147124443 cites W2113953809 @default.
• W2147124443 cites W2123950745 @default.
• W2147124443 cites W2125111380 @default.
• W2147124443 cites W2137222303 @default.
• W2147124443 cites W2140250064 @default.
• W2147124443 cites W2141575938 @default.
• W2147124443 cites W2147194233 @default.
• W2147124443 cites W2147781659 @default.
• W2147124443 cites W2150467649 @default.
• W2147124443 cites W2150995202 @default.
• W2147124443 cites W2151809142 @default.
• W2147124443 cites W2155190242 @default.
• W2147124443 cites W2155519816 @default.
• W2147124443 cites W2156190275 @default.
• W2147124443 cites W2158156749 @default.
• W2147124443 cites W2161190592 @default.
• W2147124443 cites W2162290849 @default.
• W2147124443 cites W2170780799 @default.
• W2147124443 cites W193423965 @default.
• W2147124443 doi "https://doi.org/10.1038/mtna.2012.3" @default.
• W2147124443 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3381589" @default.
• W2147124443 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23343883" @default.
• W2147124443 hasPublicationYear "2012" @default.
• W2147124443 type Work @default.
• W2147124443 sameAs 2147124443 @default.
• W2147124443 citedByCount "110" @default.
• W2147124443 countsByYear W21471244432012 @default.
• W2147124443 countsByYear W21471244432013 @default.
• W2147124443 countsByYear W21471244432014 @default.
• W2147124443 countsByYear W21471244432015 @default.
• W2147124443 countsByYear W21471244432016 @default.
• W2147124443 countsByYear W21471244432017 @default.
• W2147124443 countsByYear W21471244432018 @default.
• W2147124443 countsByYear W21471244432019 @default.
• W2147124443 countsByYear W21471244432020 @default.
• W2147124443 countsByYear W21471244432021 @default.
• W2147124443 countsByYear W21471244432022 @default.
• W2147124443 countsByYear W21471244432023 @default.
• W2147124443 crossrefType "journal-article" @default.
• W2147124443 hasAuthorship W2147124443A5020648798 @default.
• W2147124443 hasAuthorship W2147124443A5049656883 @default.
• W2147124443 hasAuthorship W2147124443A5051555445 @default.
• W2147124443 hasAuthorship W2147124443A5056877021 @default.
• W2147124443 hasAuthorship W2147124443A5078101996 @default.
• W2147124443 hasAuthorship W2147124443A5078593465 @default.
• W2147124443 hasBestOaLocation W21471244431 @default.
• W2147124443 hasConcept C104317684 @default.
• W2147124443 hasConcept C153911025 @default.
• W2147124443 hasConcept C176944494 @default.
• W2147124443 hasConcept C2778776201 @default.
• W2147124443 hasConcept C36823959 @default.
• W2147124443 hasConcept C501734568 @default.
• W2147124443 hasConcept C54355233 @default.
• W2147124443 hasConcept C54458228 @default.
• W2147124443 hasConcept C67705224 @default.
• W2147124443 hasConcept C86803240 @default.
• W2147124443 hasConceptScore W2147124443C104317684 @default.
• W2147124443 hasConceptScore W2147124443C153911025 @default.
• W2147124443 hasConceptScore W2147124443C176944494 @default.
• W2147124443 hasConceptScore W2147124443C2778776201 @default.
• W2147124443 hasConceptScore W2147124443C36823959 @default.
• W2147124443 hasConceptScore W2147124443C501734568 @default.
• W2147124443 hasConceptScore W2147124443C54355233 @default.
• W2147124443 hasConceptScore W2147124443C54458228 @default.
• W2147124443 hasConceptScore W2147124443C67705224 @default.
• W2147124443 hasConceptScore W2147124443C86803240 @default.
• W2147124443 hasLocation W21471244431 @default.

• next